Description

Mounjaro KwikPen 7.5mg Injection

MOUNJARO KwikPen 7.5mg Injection (active ingredient: tirzepatide) is a next-generation, once-weekly injectable medicine designed to help adults manage type 2 diabetes more effectively. Using a convenient pre-filled pen, MOUNJARO combines two mechanisms of action that target blood sugar control while supporting weight loss. Its unique dual agonist design sets it apart from traditional diabetes treatments, making it a top choice for modern diabetes care.​

Uses

• MOUNJARO is prescribed to improve glycemic (blood sugar) control in adults with type 2 diabetes when diet and exercise alone do not provide adequate results.

• Can be used alone if you cannot tolerate metformin, or alongside other diabetes medicines such as metformin, SGLT2 inhibitors, sulfonylureas, or insulin.​

• Clinical trials have demonstrated that MOUNJARO also helps with weight loss and can reduce blood pressure and cholesterol, adding extra cardiometabolic benefits for at-risk individuals.​

Precautions

• Not suitable for people with type 1 diabetes or those with a history of pancreatitis.​

• Use caution if you have a history of severe digestive problems, certain eye conditions (like diabetic retinopathy), or gallbladder disease.​

• May increase the risk of low blood sugar (hypoglycemia) when used with other diabetes medications—regular monitoring is required.

• Most common side effects include mild nausea, vomiting, diarrhea, indigestion, abdominal pain, and constipation. Serious but rare risks include acute pancreatitis and gallbladder disease.​

• Safe use during pregnancy or breastfeeding has not been established. Consult your healthcare provider for advice before starting MOUNJARO.​

Frequently Asked Questions

Q: How quickly does MOUNJARO start working?
A: Blood sugar control may be noticeable within weeks, with significant benefits seen after several months of regular use.​

Q: How is MOUNJARO administered?
A: Inject subcutaneously (under the skin) once a week, at any time of day, in the abdomen, thigh, or upper arm, with or without food.​

Q: Can MOUNJARO cause weight loss?
A: Yes, many patients experience significant weight reduction, which is primarily from fat loss—clinical studies show up to 10% weight loss over time.​

Q: Can I miss a dose?
A: If you miss a dose, take it as soon as possible within 4 days. If more than 4 days pass, skip the missed dose and continue with your regular schedule.​

Q: Is it safe for everyone with diabetes?
A: No, MOUNJARO is not for people with type 1 diabetes, those with a history of pancreatitis, or with certain severe digestive problems.​

Interesting Fact

MOUNJARO’s active ingredient, tirzepatide, is the first dual GIP and GLP-1 receptor agonist—a breakthrough innovation recognized by diabetes associations for superior glycemic control and weight management. The convenience of the KwikPen allows for precise dosing and storage at home, making diabetes management simpler than ever before.